SCHEMBL1624682

SCHEMBL1624682

Cc1ccc(CNc2ccccc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.84
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
MAPT P10636 2/20 0.66
HPGD P15428 2/20 0.66
KDM4E B2RXH2 1/20 0.66
ALDH1A1 P00352 1/20 0.66
POLB P06746 1/20 0.66
HSP90AA1 P07900 1/20 0.66
HSP90AB1 P08238 1/20 0.66
GAA P10253 1/20 0.66
THRB P10828 1/20 0.66
ALOX15 P16050 1/20 0.66
MAPK1 P28482 1/20 0.66
CASP1 P29466 1/20 0.66
BLM P54132 1/20 0.66
PLEC Q15149 1/20 0.66
HSD17B10 Q99714 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
CYP1A2 P05177 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17448681 0.94 HTT (0.75) HTTMEN1KMT2AMAPTHPGD
N-Benzyl-4-Methylaniline SCHEMBL171785 0.91 HTT (1.00) HTTMEN1KMT2AMAPTHPGD
N-Benzyl-4-Methylaniline SCHEMBL9771340 0.89 HTT (0.96) HTTMEN1KMT2AMAPTHPGD
N-Benzyl-4-Methylaniline SCHEMBL28183543 0.89 HTT (0.96) HTTMEN1KMT2AMAPTHPGD
SCHEMBL2005375 0.89 MAPT (0.80) HTTMEN1KMT2AMAPTHPGD
SCHEMBL10055032 0.89 MAPT (0.80) HTTMEN1KMT2AMAPTHPGD
SCHEMBL2065031 0.89 CYP1A2 (0.69) HTTMEN1KMT2AALDH1A1CYP1A2
SCHEMBL11512045 0.88 HTT (0.79) HTTMEN1KMT2AMAPTHPGD
N-Benzylaniline SCHEMBL7840 0.84 HTT (0.71) HTTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL22628164 0.84 HTT (0.71) HTTMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP claimed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO claimed
CN-119701982-A Application of niobium oxide supported copper catalyst in synthesis of secondary amine or derivative thereof from aromatic nitro compound and benzyl alcohol compound 兰州大学 2025-03-28 CN disclosed
CN-116102430-B Alkylation synthesis method for in-situ catalytic alcohols 中山大学 2025-03-14 CN disclosed
CN-119318958-A Zr(OH)4Preparation of Cu-supported bifunctional catalyst and application of Cu-supported bifunctional catalyst in catalytic synthesis of N-benzyl aniline compound 兰州大学 2025-01-17 CN disclosed
CN-117123281-B Long-acting catalyst of carbon-coated Fe-Ni alloy, and preparation method and application thereof 宁夏大学 2024-03-26 CN disclosed
CN-114409493-B Method for synthesizing 9-aryl fluorene compound 浙江工业大学 2024-02-23 CN disclosed
CN-114349587-B Method for synthesizing 9, 9-spirobifluorene compound 浙江工业大学 2024-02-23 CN disclosed
CN-117123281-A Long-acting catalyst of carbon-coated Fe-Ni alloy, and preparation method and application thereof 宁夏大学 2023-11-28 CN disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
WO-2023081967-A1 COMPOUNDS AND USES THEREFOR THE UNIVERSITY OF WESTERN AUSTRALIA (AU) 2023-05-19 WO disclosed
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN W 2007-07-05 US disclosed
US-7220781-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2007-05-22 US disclosed
EP-1009758-B1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2005-06-01 EP disclosed
US-20040143018-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-07-22 US disclosed
US-6740682-B2 TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. TULARIK LIMITED (GB) 2004-05-25 US disclosed
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2002-05-09 US disclosed
EP-1009758-A1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS Protherics Molecular Design Limited (GB) 2000-06-21 EP disclosed
WO-1999011658-A1 META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS PROTEUS MOLECULAR DESIGN LTD. (GB) 1999-03-11 WO disclosed
US-4128582-A Chemical process ETHYL CORPORATION (US) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML HTT 3116/4885MEN1 763/4885KMT2A 854/4885
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 HTT 3181/4885MEN1 458/4885KMT2A 2473/4885
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors PEPD, SERPINE1, HPN HTT 2876/4885MEN1 482/4885KMT2A 1861/4885
US-20040143018-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 HTT 3181/4885MEN1 458/4885KMT2A 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.